<DOC>
	<DOCNO>NCT02340975</DOCNO>
	<brief_summary>This randomize , multicenter , open-label , dose-exploration dose-expansion study evaluate safety , tolerability , antitumor activity , PK , pharmacodynamics , immunogenicity MEDI4736 combination tremelimumab , MEDI4736 monotherapy tremelimumab monotherapy subject metastatic recurrent gastric gastroesophageal junction adenocarcinoma</brief_summary>
	<brief_title>A Phase 1b/2 Study MEDI4736 With Tremelimumab , MEDI4736 Tremelimumab Monotherapy Gastric GEJ Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<criteria>1 . Male female subject 2 . 18 year old 3 . Histological cytological confirmation metastatic recurrent gastric gastroesophageal junction adenocarcinoma 4 . Subjects must receive progressed , refractory standard regimens 5 . Prior line therapy : 1 . For Phase 1b : Must receive progressed , refractory one systemic platinum fluoropyrimidinebased chemotherapy regimen metastatic recurrent disease . 2 . For Arms A , B , C Phase 2 : Must receive progressed , arerefractory one systemic platinum fluoropyrimidinebased chemotherapy regimen metastatic recurrent disease , Must receive progressed , refractory one systemic platinumor fluoropyrimidinebased therapy part neoadjuvant adjuvant regimen withrelapse within 6 month therapy . 3 . For Arm D Phase 2 : Must receive progressed , refractory totwo systemic regimen ( one standard platinum fluoropyrimidinebasedchemotherapy regimen one approve regimen ) metastatic recurrent disease . 4 . Subjects receive progressed , refractory one systemicplatinum fluoropyrimidinebased therapy part neoadjuvant adjuvantregimen relapse within 6 month count line therapy metastatic/recurrent set . 1 . Any concurrent chemotherapy , immunotherapy , biologic , hormonal therapy cancer treatment 2 . Previous immunemediated therapy 3 . Concurrent prior use immunosuppressive medication 14 day 4 . Active prior document autoimmune inflammatory disease within 3 year exception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Gastric Adenocarcinoma</keyword>
	<keyword>Gastroesophageal Junction Adenocarcinoma</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Tremelimumab</keyword>
	<keyword>MEDI4736</keyword>
</DOC>